相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。A comparative view on the expression patterns of PD-L1 and PD-1 in soft tissue sarcomas
Martin F. Orth et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2020)
Randomized Comparison of Pazopanib and Doxorubicin as First-Line Treatment in Patients With Metastatic Soft Tissue Sarcoma Age 60 Years or Older: Results of a German Intergroup Study
Viktor Gruenwald et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Functional genomics identifies AMPD2 as a new prognostic marker for undifferentiated pleomorphic sarcoma
Martin F. Orth et al.
INTERNATIONAL JOURNAL OF CANCER (2019)
Degree of MDM2 Amplification Affects Clinical Outcomes in Dedifferentiated Liposarcoma
Kate Lynn J. Bill et al.
ONCOLOGIST (2019)
The Inhibition of miR-144-3p on Cell Proliferation and Metastasis by Targeting TOP2A in HCMV-Positive Glioblastoma Cells
Jingyi Song et al.
MOLECULES (2018)
Gemcitabine and docetaxel versus doxorubicin as first-line treatment in previously untreated advanced unresectable or metastatic soft-tissue sarcomas (GeDDiS): a randomised controlled phase 3 trial
Beatrice Seddon et al.
LANCET ONCOLOGY (2017)
Histotype-tailored neoadjuvant chemotherapy versus standard chemotherapy in patients with high-risk soft-tissue sarcomas (ISG-STS 1001): an international, open-label, randomised, controlled, phase 3, multicentre trial
Alessandro Gronchi et al.
LANCET ONCOLOGY (2017)
TOP2A copy number and TOP2A expression in uterine benign smooth muscle tumours and leiomyosarcoma
Glauco Baiocchi et al.
JOURNAL OF CLINICAL PATHOLOGY (2016)
Development and external validation of two nomograms to predict overall survival and occurrence of distant metastases in adults after surgical resection of localised soft-tissue sarcomas of the extremities: a retrospective analysis
Dario Callegaro et al.
LANCET ONCOLOGY (2016)
Mechanisms of doxorubicin resistance in hepatocellular carcinoma
Josiah Cox et al.
HEPATIC ONCOLOGY (2016)
SIRT1 and SIRT2 inhibition impairs pediatric soft tissue sarcoma growth
L. Ma et al.
CELL DEATH & DISEASE (2014)
SIRT1 expression is associated with a poor prognosis, whereas DBC1 is associated with favorable outcomes in gastric cancer
Akira Noguchi et al.
CANCER MEDICINE (2014)
Expression of SIRT1 and DBC1 Is Associated with Poor Prognosis of Soft Tissue Sarcomas
Jung Ryul Kim et al.
PLOS ONE (2013)
Prognostication of Soft Tissue Sarcomas Based on Chromosome 17q Gene and Protein Status: Evaluation of TOP2A, HER-2/neu, and Survivin
Isabela Werneck da Cunha et al.
ANNALS OF SURGICAL ONCOLOGY (2012)
Hyperthermia in soft tissue sarcoma
Lars H. Lindner et al.
CURRENT TREATMENT OPTIONS IN ONCOLOGY (2011)
Topoisomerase II-alpha protein expression and histological response following doxorubicin-based induction chemotherapy predict survival of locally advanced soft tissues sarcomas
Ruiz-Soto Rodrigo et al.
EUROPEAN JOURNAL OF CANCER (2011)
Neo-adjuvant chemotherapy alone or with regional hyperthermia for localised high-risk soft-tissue sarcoma: a randomised phase 3 multicentre study
Rolf D. Issels et al.
LANCET ONCOLOGY (2010)
New perspectives for staging and prognosis in soft tissue sarcoma
G. Lahat et al.
ANNALS OF SURGICAL ONCOLOGY (2008)
Interplay among BRCA1, SIRT1, and Survivin during BRCA1-Associated Tumorigenesis
Rui-Hong Wang et al.
MOLECULAR CELL (2008)
The SIRT1 Deacetylase Suppresses Intestinal Tumorigenesis and Colon Cancer Growth
Ron Firestein et al.
PLOS ONE (2008)
Control of multidrug resistance gene mdr1 and cancer resistance to chemotherapy by the longevity gene sirt1
F Chu et al.
CANCER RESEARCH (2005)
Immunoprofiles of 11 biomarkers using tissue microarrays identify prognostic subgroups in colorectal cancer
T Knösel et al.
NEOPLASIA (2005)
Predicting response to methotrexate, vinblastine, doxorubicin, and cisplatin neoadjuvant chemotherapy for bladder cancers through genome-wide gene expression profiling
R Takata et al.
CLINICAL CANCER RESEARCH (2005)
Molecular mechanisms of drug resistance
DB Longley et al.
JOURNAL OF PATHOLOGY (2005)
Topoisomerase-IIα is upregulated in malignant peripheral nerve sheath tumors and associated with clinical outcome
RI Skotheim et al.
JOURNAL OF CLINICAL ONCOLOGY (2003)
Nuclear expression of Y-box-binding protein-1 correlates with P-glycoprotein and topoisomerase II alpha expression, and with poor prognosis in synovial sarcoma
Y Oda et al.
JOURNAL OF PATHOLOGY (2003)
Negative control of p53 by Sir2α promotes cell survival under stress
JY Luo et al.
CELL (2001)
hSIR2SIRT1 functions as an NAD-dependent p53 deacetylase
H Vaziri et al.
CELL (2001)
Atypical multidrug resistance may be associated with catalytically active mutants of human DNA topoisomerase II α
Y Okada et al.
GENE (2001)
分享论文
